Skip to main
OCS

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding is a clinical-stage biopharmaceutical company focused on addressing unmet needs in the eye care market. With a pipeline of innovative drug candidates, including OCS-01 for diabetic macular edema (DME), OCS-02 for dry eye disease (DED), and OCS-05 for neuro-ophthalmic diseases, the company has the potential to become a leading player in this sector. Despite a recent setback in the Phase III DIAMOND-1 and DIAMOND-2 trials of OCS-01 in DME, the company's strong balance sheet and promising pipeline warrant a positive outlook. Key factors to consider include the potential of OCS-02 as the first precision medicine for DED and the neuroprotective properties of OCS-05, which could have multiple blockbuster indications. Overall, the company's diverse portfolio and potential for both near-term and long-term growth make it a promising investment opportunity.

Bears say

Oculis Holding is facing potential clinical trial failure, competition with other late-stage development candidates, commercialization risk, and financial risk. These risks, combined with the company's lack of current revenue and profitability, lead to a negative outlook on the stock.

OCS has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 9 analysts, OCS has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.